邦耀生物入选“上海市市级企业技术中心”，助力全球基因与细胞治疗创新

Core Viewpoint - Shanghai Bangyao Biotechnology Co., Ltd. has been recognized as a city-level enterprise technology center, highlighting its innovation capabilities and achievements in the field of gene and cell therapy [1][6][20]. Group 1: Recognition and Achievements - The recognition as a city-level enterprise technology center is a significant credential for Bangyao Biotechnology, following its previous accolades as a national intellectual property advantage enterprise and a Shanghai patent demonstration unit [1][2]. - This recognition reflects the company's leading position in the CGT (cell and gene therapy) sector, showcasing its organizational structure, management mechanisms, innovation efficiency, talent development, and technological achievements [6][20]. Group 2: Technological Platforms and Innovations - Bangyao Biotechnology has established five proprietary technology platforms: CRISTARS (gene editing technology innovation platform), ModiHSC (hematopoietic stem cell platform), Quikin CART (non-viral site-specific integration CAR-T platform), TyUCell (universal cell platform), and HyperTCell (enhanced T cell platform) [8][23]. - The company has generated over 100 patent achievements and has more than 10 innovative drug pipelines, with 5 projects having received IND (Investigational New Drug) approval in China, entering the registration clinical trial phase [8][23]. Group 3: Notable Products and Clinical Trials - The first product, BRL-101, is the world's first gene therapy for β0/β0 thalassemia using CRISPR/Cas9 technology, which has helped 15 patients become completely independent of blood transfusions [9][10]. - The non-viral site-specific integration CAR-T therapies, BRL-201 and BRL-203, have shown a 100% objective response rate in clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma [12][14]. - The allogeneic universal CAR-T therapies, BRL-301 and BRL-303, have been developed to address the risks of host rejection and graft-versus-host disease, significantly reducing production costs and patient wait times [15][18]. Group 4: Future Outlook - The recognition as a city-level enterprise technology center not only affirms Bangyao Biotechnology's past achievements but also sets expectations for its future development [20][21]. - The company aims to continue collaborating with global partners to enhance basic research and promote the clinical advancement of innovative products, contributing to the development of the CGT field in China [20][21].